Patents Examined by Jeffrey S. Lundgren
  • Patent number: 12006296
    Abstract: A 5-(4-methoxyphenyl)-1-hexyl-2-(4-nitrophenyl)-4-phenyl-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: June 11, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 12006278
    Abstract: An 4,4?-naphthalene-1,5-diylbis(diazene-2,1-diyl)diphenol compound, its synthesis, and its use as an antioxidant agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: June 11, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 12006301
    Abstract: Novel dual 5-HT1A and 5-HT7 receptor ligands and methods of using the novel ligands to treat a neurological disorder are presented.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: June 11, 2024
    Assignee: Florida A&M University
    Inventor: Seth Y. Ablordeppey
  • Patent number: 12006310
    Abstract: The present invention relates to the technical field of natural medicines, and in particular to a triterpenoid compound with an effect of improving glucose and lipid metabolism disorders, and preparation and application thereof. A novel triterpenoid compound was obtained by separation from Momordica charantia L. for the first time in the present invention. Studies on a mouse primary hepatocyte model and a 3T3-L1 preadipocyte model show that the novel triterpenoid compound in the present invention has activity of regulating glucose and lipid metabolism, and after combination with known triterpenoid compound Momordicoside G, the activity of regulating glucose and lipid metabolism is significantly higher than that of a single compound at the same dose, indicating that the novel triterpenoid compound and a complex thereof in the present invention can be used to improve glucose and lipid metabolism disorders and provide a new way for diabetes treatment.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: June 11, 2024
    Assignee: SERICULTURAL & AGRI-FOOD RESEARCH INSTITUTE GUANGDONG ACADEMY OF AGRICULTERAL SCIENCES
    Inventors: Mingwei Zhang, Yuanyuan Deng, Guang Liu, Yan Zhang, Zhencheng Wei, Pengfei Zhou, Ping Li, Zhihao Zhao, Xuchao Jia, Xiaojun Tang
  • Patent number: 11999724
    Abstract: The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine rings without using palladium, a strong base, or a high-temperature reaction. In particular, they successfully developed a method that can be used to synthesize iminium salts as intermediates, synthesize cyano compounds from these iminium salts, and cyclize the cyano compounds into pyridines under very mild reaction conditions.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: June 4, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuichi Aki, Fumihiko Toriyama, Natsuki Sakurai, Ai Kameda, Tomokazu Ogura
  • Patent number: 11999676
    Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: June 4, 2024
    Assignee: University of Kentucky Research Foundation
    Inventors: Linda P. Dwoskin, David Watt, Jon Thorson, Mark Leggas, Kip Guy, Jared Hammill, Stefan Kwiatkowski, Derong Ding, Guangrong Zheng, Peter Anthony Crooks, Na-Ra Lee
  • Patent number: 11998519
    Abstract: Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and/or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: June 4, 2024
    Inventor: Rob D. Dickerman
  • Patent number: 11999716
    Abstract: Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: June 4, 2024
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Joseph R. Alvarado, Jianhua Tian, Kenneth M. Meyers, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Shaun R. Stauffer, Stephen W. Fesik, Rocco D. Gogliotti
  • Patent number: 11993600
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: May 28, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
  • Patent number: 11986454
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: June 22, 2023
    Date of Patent: May 21, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11987543
    Abstract: An 8-(4-bromobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11986455
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: May 21, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11981683
    Abstract: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: March 19, 2022
    Date of Patent: May 14, 2024
    Assignee: Arvinas Operations, Inc.
    Inventors: Erika Marina Vieira Araujo, Michael Berlin, Hanqing Dong, Steven M. Sparks, Jing Wang, Wei Zhang
  • Patent number: 11976069
    Abstract: The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 7, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Wensheng Yu, Joseph A. Kozlowski, Dane James Clausen, Jian Liu, James Fells
  • Patent number: 11974972
    Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: May 7, 2024
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Joong Ho Moon, Michelle Miranda
  • Patent number: 11975009
    Abstract: The present disclosure provides for a method of inhibiting the growth of a microorganism including contacting the microorganism with zinc porphyrin (ZnPor). The present disclosure also provides for a method of treating or preventing biofilm formation of one or more microorganisms including contacting the biofilm with zinc porphyrin (ZnPor). Further, the present disclosure provides for a method of treating a disease associated with biofilm formation in a subject including administering to the subject a composition comprising a therapeutically effective amount of ZnPor.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: May 7, 2024
    Assignee: ZNABLE LLC
    Inventor: Jayne Robinson
  • Patent number: 11969404
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: April 30, 2024
    Assignee: AXSOME MALTA LTD.
    Inventor: Katayoun Zomorodi
  • Patent number: 11964987
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Achyutharao Sidduri
  • Patent number: 11957752
    Abstract: The present invention relates to the technical field of photosensitizers, and particularly to a near-infrared nano-photosensitizer and a preparation method and use thereof. The near-infrared nano-photosensitizer in the present invention is modified by conjugation extension of the boron dipyrromethene core, achieving absorption and emission spectra close to the near-infrared region. A polyfluoroalkyl group and a polyethylene glycol group are introduced to the boron dipyrromethene structure to obtain an amphiphilic photosensitizer. By means of the strong fluorine-fluorine interaction between the polyfluoroalkyl group and the hydrophilic interaction of the polyethylene glycol group, a nano-photosensitive micelle with an ultra-low CMC value is ultimately constructed. Boron dipyrromethene is induced by fluorine-fluorine interaction to undergo J-aggregation, causing the maximum absorption peak to red-shift to the near-infrared region, beneficial to the deep phototherapy of tumors.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: April 16, 2024
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Zhengqing Guo, Hui He, Mengke Shi, Han Xu, Dandan Ji, Yangyang Huang, Qiujin He
  • Patent number: 11958835
    Abstract: A 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(4-chlorophenyl)-2-alkoxynicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer